| Home | Search | Study Topics | Glossary |
|
|
|
 |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||
| Sponsored by: |
National Cancer Institute (NCI) |
| Information provided by: | National Cancer Institute (NCI) |
| ClinicalTrials.gov Identifier: | NCT00018954 |
Purpose
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
PURPOSE: Phase II trial to study the effectiveness of two treatment regimens for patients in developing countries with diffuse non-Hodgkin's lymphoma and acute lymphoblastic leukemia.
| Condition | Intervention | Phase |
|
Leukemia Lymphoma |
Drug: asparaginase Drug: cyclophosphamide Drug: cytarabine Drug: daunorubicin hydrochloride Drug: doxorubicin hydrochloride Drug: etoposide Drug: ifosfamide Drug: mercaptopurine Drug: methotrexate Drug: prednisone Drug: vincristine sulfate Procedure: conventional surgery Procedure: radiation therapy |
Phase II |
| MedlinePlus related topics: | Cancer Leukemia, Adult Acute Leukemia, Adult Chronic Leukemia, Childhood Lymphoma |
| Study Type: | Interventional |
| Study Design: | Treatment |
| Official Title: | PILOT MULTINATIONAL PROTOCOLS IN ACUTE LYMPHOBLASTIC LEUKEMIA AND DIFFUSE NON-HODGKIN'S LYMPHOMA |
Eligibility
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS:
Newly diagnosed acute lymphoblastic leukemia (ALL)
Lymphoblasts comprising more than 25% of nucleated cells on bone marrow aspirate
PATIENT CHARACTERISTICS:
Age:
ALL:
NHL:
Performance status:
Life expectancy:
Hematopoietic:
Hepatic:
Renal:
PRIOR CONCURRENT THERAPY:
Biologic therapy
Chemotherapy
Endocrine therapy
Radiotherapy
Surgery
Other
Contacts and Locations| United States, Maryland | |||||
| Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support | |||||
| Bethesda, Maryland, United States, 20892-1182 | |||||
| Egypt | |||||
| National Cancer Institute of Egypt | |||||
| Cairo, Egypt | |||||
| India | |||||
| Cancer Institute (W.I.A.) | |||||
| Madras, India, 600020 | |||||
| Kidwai Memorial Institute of Oncology | |||||
| Bangalore, India, 560029 | |||||
| Tata Memorial Centre | |||||
| Mumbai, India, 400012 | |||||
| Study Chair: | Ian Trevor Magrath, MD, FRCP, FRCPath | NCI - Pediatric Oncology Branch |
More Information
Clinical trial summary from the National Cancer Institute's PDQ® database
|
| Study ID Numbers: | CDR0000077227, NCI-92-C-0030, NCI-T91-0259N |
| First Received: | July 11, 2001 |
| Last Updated: | August 23, 2008 |
| ClinicalTrials.gov Identifier: | NCT00018954 |
| Health Authority: | United States: Federal Government |
|
|
|
|
|
|
|
